[1]
Swerdlow SH,Campo E,Pileri SA,Harris NL,Stein H,Siebert R,Advani R,Ghielmini M,Salles GA,Zelenetz AD,Jaffe ES, The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19;
[PubMed PMID: 26980727]
[2]
Olszewski AJ,Castillo JJ, Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2013 Feb 1;
[PubMed PMID: 22893605]
[3]
Zucca E,Bertoni F,Vannata B,Cavalli F, Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Oct 15;
[PubMed PMID: 25320370]
[4]
Roggero E,Zucca E,Mainetti C,Bertoni F,Valsangiacomo C,Pedrinis E,Borisch B,Piffaretti JC,Cavalli F,Isaacson PG, Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Human pathology. 2000 Feb;
[PubMed PMID: 10685647]
[5]
Ferreri AJ,Guidoboni M,Ponzoni M,De Conciliis C,Dell'Oro S,Fleischhauer K,Caggiari L,Lettini AA,Dal Cin E,Ieri R,Freschi M,Villa E,Boiocchi M,Dolcetti R, Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. Journal of the National Cancer Institute. 2004 Apr 21;
[PubMed PMID: 15100336]
[6]
Lecuit M,Abachin E,Martin A,Poyart C,Pochart P,Suarez F,Bengoufa D,Feuillard J,Lavergne A,Gordon JI,Berche P,Guillevin L,Lortholary O, Immunoproliferative small intestinal disease associated with Campylobacter jejuni. The New England journal of medicine. 2004 Jan 15;
[PubMed PMID: 14724303]
[7]
Adam P,Czapiewski P,Colak S,Kosmidis P,Tousseyn T,Sagaert X,Boudova L,Okoń K,Morresi-Hauf A,Agostinelli C,Pileri S,Pruneri G,Martinelli G,Du MQ,Fend F, Prevalence of Achromobacter xylosoxidans in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe. British journal of haematology. 2014 Mar;
[PubMed PMID: 24372375]
[8]
Arcaini L,Merli M,Volpetti S,Rattotti S,Gotti M,Zaja F, Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. Clinical
[PubMed PMID: 22956970]
[9]
Zintzaras E,Voulgarelis M,Moutsopoulos HM, The risk of lymphoma development in autoimmune diseases: a meta-analysis. Archives of internal medicine. 2005 Nov 14;
[PubMed PMID: 16287762]
Level 1 (high-level) evidence
[10]
Nocturne G,Mariette X, Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management. British journal of haematology. 2015 Feb;
[PubMed PMID: 25316606]
[11]
Khalil MO,Morton LM,Devesa SS,Check DP,Curtis RE,Weisenburger DD,Dores GM, Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site. British journal of haematology. 2014 Apr;
[PubMed PMID: 24417667]
[12]
Zucca E,Bertoni F,Roggero E,Cavalli F, The gastric marginal zone B-cell lymphoma of MALT type. Blood. 2000 Jul 15;
[PubMed PMID: 10887100]
[13]
White WL,Ferry JA,Harris NL,Grove AS Jr, Ocular adnexal lymphoma. A clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type. Ophthalmology. 1995 Dec;
[PubMed PMID: 9098307]
[14]
Rosado MF,Byrne GE Jr,Ding F,Fields KA,Ruiz P,Dubovy SR,Walker GR,Markoe A,Lossos IS, Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood. 2006 Jan 15;
[PubMed PMID: 16166588]
[15]
Borie R,Wislez M,Thabut G,Antoine M,Rabbat A,Couderc LJ,Monnet I,Nunes H,Blanc FX,Mal H,Bergeron A,Dusser D,Israël-Biet D,Crestani B,Cadranel J, Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. The European respiratory journal. 2009 Dec;
[PubMed PMID: 19541720]
[16]
Al-Saleem T,Al-Mondhiry H, Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood. 2005 Mar 15;
[PubMed PMID: 15542584]
[17]
Rinaldi A,Mian M,Chigrinova E,Arcaini L,Bhagat G,Novak U,Rancoita PM,De Campos CP,Forconi F,Gascoyne RD,Facchetti F,Ponzoni M,Govi S,Ferreri AJ,Mollejo M,Piris MA,Baldini L,Soulier J,Thieblemont C,Canzonieri V,Gattei V,Marasca R,Franceschetti S,Gaidano G,Tucci A,Uccella S,Tibiletti MG,Dirnhofer S,Tripodo C,Doglioni C,Dalla Favera R,Cavalli F,Zucca E,Kwee I,Bertoni F, Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood. 2011 Feb 3;
[PubMed PMID: 21115979]
Level 2 (mid-level) evidence
[18]
Remstein ED,Dogan A,Einerson RR,Paternoster SF,Fink SR,Law M,Dewald GW,Kurtin PJ, The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. The American journal of surgical pathology. 2006 Dec;
[PubMed PMID: 17122510]
[19]
Ye H,Liu H,Attygalle A,Wotherspoon AC,Nicholson AG,Charlotte F,Leblond V,Speight P,Goodlad J,Lavergne-Slove A,Martin-Subero JI,Siebert R,Dogan A,Isaacson PG,Du MQ, Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood. 2003 Aug 1;
[PubMed PMID: 12676782]
[20]
Jost PJ,Ruland J, Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007 Apr 1;
[PubMed PMID: 17119127]
[21]
Baens M,Fevery S,Sagaert X,Noels H,Hagens S,Broeckx V,Billiau AD,De Wolf-Peeters C,Marynen P, Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination. Cancer research. 2006 May 15;
[PubMed PMID: 16707452]
[22]
Schmid C,Kirkham N,Diss T,Isaacson PG, Splenic marginal zone cell lymphoma. The American journal of surgical pathology. 1992 May;
[PubMed PMID: 1599024]
[23]
Dreyling M,Thieblemont C,Gallamini A,Arcaini L,Campo E,Hermine O,Kluin-Nelemans JC,Ladetto M,Le Gouill S,Iannitto E,Pileri S,Rodriguez J,Schmitz N,Wotherspoon A,Zinzani P,Zucca E, ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Apr;
[PubMed PMID: 23425945]
Level 3 (low-level) evidence
[24]
Zucca E,Conconi A,Pedrinis E,Cortelazzo S,Motta T,Gospodarowicz MK,Patterson BJ,Ferreri AJ,Ponzoni M,Devizzi L,Giardini R,Pinotti G,Capella C,Zinzani PL,Pileri S,López-Guillermo A,Campo E,Ambrosetti A,Baldini L,Cavalli F, Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003 Apr 1;
[PubMed PMID: 12456507]
[25]
Tu PH,Giannini C,Judkins AR,Schwalb JM,Burack R,O'Neill BP,Yachnis AT,Burger PC,Scheithauer BW,Perry A, Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Aug 20;
[PubMed PMID: 16009945]
[26]
Servitje O,Gallardo F,Estrach T,Pujol RM,Blanco A,Fernández-Sevilla A,Pétriz L,Peyrí J,Romagosa V, Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. The British journal of dermatology. 2002 Dec;
[PubMed PMID: 12452864]
Level 3 (low-level) evidence
[27]
Ferry JA,Fung CY,Zukerberg L,Lucarelli MJ,Hasserjian RP,Preffer FI,Harris NL, Lymphoma of the ocular adnexa: A study of 353 cases. The American journal of surgical pathology. 2007 Feb;
[PubMed PMID: 17255761]
Level 3 (low-level) evidence
[28]
Teckie S,Qi S,Chelius M,Lovie S,Hsu M,Noy A,Portlock C,Yahalom J, Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 May 1;
[PubMed PMID: 28327924]
Level 2 (mid-level) evidence
[29]
Koch P,del Valle F,Berdel WE,Willich NA,Reers B,Hiddemann W,Grothaus-Pinke B,Reinartz G,Brockmann J,Temmesfeld A,Schmitz R,Rübe C,Probst A,Jaenke G,Bodenstein H,Junker A,Pott C,Schultze J,Heinecke A,Parwaresch R,Tiemann M, Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Sep 15;
[PubMed PMID: 11559724]
Level 2 (mid-level) evidence
[30]
Wang T,Gui W,Shen Q, Primary gastrointestinal non-Hodgkin's lymphoma: clinicopathological and prognostic analysis. Medical oncology (Northwood, London, England). 2010 Sep;
[PubMed PMID: 19565363]
[31]
Jackson AE,Mian M,Kalpadakis C,Pangalis GA,Stathis A,Porro E,Conconi A,Cortelazzo S,Gaidano G,Lopez Guillermo A,Johnson PW,Martelli M,Martinelli G,Thieblemont C,McPhail ED,Copie-Bergman C,Pileri SA,Jack A,Campo E,Mazzucchelli L,Ristow K,Habermann TM,Cavalli F,Nowakowski GS,Zucca E, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). The oncologist. 2015 Oct;
[PubMed PMID: 26268740]
[32]
Raderer M,Kiesewetter B,Ferreri AJ, Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA: a cancer journal for clinicians. 2016 Mar-Apr;
[PubMed PMID: 26773441]
[33]
Ruskoné-Fourmestraux A,Dragosics B,Morgner A,Wotherspoon A,De Jong D, Paris staging system for primary gastrointestinal lymphomas. Gut. 2003 Jun;
[PubMed PMID: 12740354]
[34]
Zullo A,Hassan C,Cristofari F,Andriani A,De Francesco V,Ierardi E,Tomao S,Stolte M,Morini S,Vaira D, Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2010 Feb;
[PubMed PMID: 19631287]
[35]
Stathis A,Chini C,Bertoni F,Proserpio I,Capella C,Mazzucchelli L,Pedrinis E,Cavalli F,Pinotti G,Zucca E, Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Jun;
[PubMed PMID: 19193705]
Level 2 (mid-level) evidence
[36]
Wotherspoon AC,Doglioni C,Diss TC,Pan L,Moschini A,de Boni M,Isaacson PG, Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet (London, England). 1993 Sep 4;
[PubMed PMID: 8102719]
[37]
Govi S,Dognini GP,Licata G,Crocchiolo R,Resti AG,Ponzoni M,Ferreri AJ, Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. British journal of haematology. 2010 Jul;
[PubMed PMID: 20433679]
[38]
Tomita N,Kodaira T,Tachibana H,Nakamura T,Mizoguchi N,Takada A, Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2009 Feb;
[PubMed PMID: 19135751]
[39]
Wirth A,Gospodarowicz M,Aleman BM,Bressel M,Ng A,Chao M,Hoppe RT,Thieblemont C,Tsang R,Moser L,Specht L,Szpytma T,Lennard A,Seymour JF,Zucca E, Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 May;
[PubMed PMID: 23293112]
Level 2 (mid-level) evidence
[40]
Ruskoné-Fourmestraux A,Matysiak-Budnik T,Fabiani B,Cervera P,Brixi H,Le Malicot K,Nion-Larmurier I,Fléjou JF,Hennequin C,Quéro L, Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma: Results of a prospective study with a long term follow-up. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2015 Oct;
[PubMed PMID: 26395311]
[41]
Pinnix CC,Gunther JR,Milgrom SA,Cruz Chamorro RJ,Medeiros LJ,Khoury JD,Amini B,Neelapu S,Lee HJ,Westin J,Fowler N,Nastoupil L,Dabaja B, Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. International journal of radiation oncology, biology, physics. 2019 Jun 1;
[PubMed PMID: 30769175]
[42]
Martinelli G,Laszlo D,Ferreri AJ,Pruneri G,Ponzoni M,Conconi A,Crosta C,Pedrinis E,Bertoni F,Calabrese L,Zucca E, Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Mar 20;
[PubMed PMID: 15668468]
[44]
Zucca E,Conconi A,Laszlo D,López-Guillermo A,Bouabdallah R,Coiffier B,Sebban C,Jardin F,Vitolo U,Morschhauser F,Pileri SA,Copie-Bergman C,Campo E,Jack A,Floriani I,Johnson P,Martelli M,Cavalli F,Martinelli G,Thieblemont C, Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Feb 10;
[PubMed PMID: 23295789]
Level 1 (high-level) evidence
[45]
Zucca E,Conconi A,Martinelli G,Bouabdallah R,Tucci A,Vitolo U,Martelli M,Pettengell R,Salles G,Sebban C,Guillermo AL,Pinotti G,Devizzi L,Morschhauser F,Tilly H,Torri V,Hohaus S,Ferreri AJM,Zachée P,Bosly A,Haioun C,Stelitano C,Bellei M,Ponzoni M,Moreau A,Jack A,Campo E,Mazzucchelli L,Cavalli F,Johnson P,Thieblemont C, Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jun 10;
[PubMed PMID: 28355112]
Level 1 (high-level) evidence
[46]
Rummel MJ,Niederle N,Maschmeyer G,Banat GA,von Grünhagen U,Losem C,Kofahl-Krause D,Heil G,Welslau M,Balser C,Kaiser U,Weidmann E,Dürk H,Ballo H,Stauch M,Roller F,Barth J,Hoelzer D,Hinke A,Brugger W, Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet (London, England). 2013 Apr 6;
[PubMed PMID: 23433739]
Level 1 (high-level) evidence
[47]
Flinn IW,van der Jagt R,Kahl BS,Wood P,Hawkins TE,Macdonald D,Hertzberg M,Kwan YL,Simpson D,Craig M,Kolibaba K,Issa S,Clementi R,Hallman DM,Munteanu M,Chen L,Burke JM, Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;
[PubMed PMID: 24591201]
Level 1 (high-level) evidence
[48]
Kiesewetter B,Willenbacher E,Willenbacher W,Egle A,Neumeister P,Voskova D,Mayerhoefer ME,Simonitsch-Klupp I,Melchardt T,Greil R,Raderer M, A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood. 2017 Jan 19;
[PubMed PMID: 27879257]
[49]
Noy A,de Vos S,Thieblemont C,Martin P,Flowers CR,Morschhauser F,Collins GP,Ma S,Coleman M,Peles S,Smith S,Barrientos JC,Smith A,Munneke B,Dimery I,Beaupre DM,Chen R, Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017 Apr 20;
[PubMed PMID: 28167659]
[50]
Gopal AK,Kahl BS,de Vos S,Wagner-Johnston ND,Schuster SJ,Jurczak WJ,Flinn IW,Flowers CR,Martin P,Viardot A,Blum KA,Goy AH,Davies AJ,Zinzani PL,Dreyling M,Johnson D,Miller LL,Holes L,Li D,Dansey RD,Godfrey WR,Salles GA, PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. The New England journal of medicine. 2014 Mar 13;
[PubMed PMID: 24450858]
[51]
Avivi I,Arcaini L,Ferretti VV,Boumendil A,Finel H,Milone G,Zaja F,Liliana D,Musso M,Didier B,Bachy E,Wattad M,Nicolas-Virelizier E,Gramatzki M,Bourhis JH,Caillot D,Haenel A,Held G,Thieblemont C,Jindra P,Pohlreich D,Guilhot F,Kroschinsky F,Wahlin B,Scheid C,Ifrah N,Berthou C,Dreger P,Montoto S,Conconi A, High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. British journal of haematology. 2018 Sep;
[PubMed PMID: 29984825]
Level 2 (mid-level) evidence
[52]
Thieblemont C,Cascione L,Conconi A,Kiesewetter B,Raderer M,Gaidano G,Martelli M,Laszlo D,Coiffier B,Lopez Guillermo A,Torri V,Cavalli F,Johnson PW,Zucca E, A MALT lymphoma prognostic index. Blood. 2017 Sep 21;
[PubMed PMID: 28720586]
[53]
Alderuccio JP,Zhao W,Desai A,Gallastegui N,Ramdial J,Kimble E,de la Fuente MI,Rosenblatt JD,Chapman JR,Vega F,Reis IM,Lossos IS, Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Oct 12;
[PubMed PMID: 30312133]